Vertex Pharmaceuticals Deferred Foreign Tax Expense (Benefit) remained flat by 0.0% to $9.58M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 72.4%, from $34.65M to $9.58M. Over 2 years (FY 2023 to FY 2025), Deferred Foreign Tax Expense (Benefit) shows a downward trend with a -16.8% CAGR.
Changes indicate shifts in the timing of tax payments across international jurisdictions, often driven by capital investment cycles.
The amount of income tax expense related to foreign jurisdictions that is deferred to future periods due to temporary di...
Standard disclosure for multinational corporations; comparable to deferred tax provisions reported by global industrial peers.
cat_deferred_foreign_tax_expense| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $55.30M | $138.60M | $38.30M |
| YoY Change | — | +150.6% | -72.4% |